covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Tratamiento de la diabetes mellitus tipo 2 con insulina
Journal Information
Vol. 55. Issue S2.
Guía de actualización en el tratamiento de la diabetes tipo 2 y sus complicaciones
Pages 53-57 (March 2008)
Share
Share
Download PDF
More article options
Vol. 55. Issue S2.
Guía de actualización en el tratamiento de la diabetes tipo 2 y sus complicaciones
Pages 53-57 (March 2008)
Guía de actualización en el tratamiento de la diabetes tipo 2 y sus complicaciones
Full text access
Tratamiento de la diabetes mellitus tipo 2 con insulina
Insulin therapy in type 2 diabetes
Visits
13868
E. Solá Izquierdoa,b, K. García Malpartidaa, A. Hernández Mijaresa,b,
Corresponding author
hernandez_antmij@gva.es

Correspondencia: Dr. A. Hernández Mijares. Servicio de Endocrinología y Nutrición. Hospital Universitario Doctor Peset. Avda. Gaspar Aguilar, 90. 46017 Valencia. España.
a Servicio de Endocrinología y Nutrición. Hospital Universitario Doctor Peset. Valencia. España
b Departamento de Medicina. Universitat de Valencia. Valencia. España
This item has received
Article information

En la evolución natural de la diabetes mellitus tipo 2, la capacidad secretora de insulina por el páncreas se agota de forma progresiva, empeorando el control glucémico. Por ello, en la historia natural del paciente diabético tipo 2, el tratamiento suele pasar de dieta y ejercicio físico a antidiabéticos orales y, finalmente, suele ser necesario el tratamiento con insulina para lograr un buen control metabólico. Cuando aún existe reserva pancreática, la asociación de insulina a antidiabéticos orales es la mejor opción, y puede optarse por utilizar una dosis de análogo de acción lenta, de insulina premezclada o de insulina NPH.

Cuando la reserva pancreática está agotada o cuando no se logra un buen control del paciente con una única dosis de insulina, se debe plantear el tratamiento con varias dosis de insulina premezclada, o bien el régimen basal-bolo. La decisión entre ambos tipos de tratamiento debe realizarse de forma individual, en función de las características individuales del paciente.

Palabras clave:
Insulina
Diabetes mellitus tipo 2
Tratamiento

In the natural history of type 2 diabetes, pancreatic insulin secretion is progressively depleted and metabolic control worsens. Treatment of these patients usually starts with diet and exercise, with subsequent use of oral glucose-lowering drugs, finally ending with insulin therapy to achieve good metabolic control. When there is still endogenous insulin secretion, the combination of insulin and oral glucose-lowering drugs is usually preferred, using a once-daily long-acting insulin analog, premixed insulin, or NPH insulin. When the patient no longer has any endogenous insulin secretion, or when good metabolic control cannot be achieved with a once-daily regimen, treatment with several insulin doses is required. This treatment consists of a basal-bolus regimen or several doses of premixed insulin. The choice between the 2 types of treatment should be based on the patient's individual characteristics.

Key words:
Insulin
Type 2 diabetes
Treatment
Full text is only aviable in PDF
Bibliografía
[1.]
American Diabetes Association.
Standards of Medical Care in Diabetes 2007.
Diabetes Care, 30 (2007), pp. S4-S41
[2.]
UK Prospective Diabetes Study (UKPDS) Group.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-853
[3.]
D.A. Hepburn, K.M. MacLeod, A.C. Pell, I.J. Scougla, B.M. Frier.
Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin.
Diabet Med, 10 (1993), pp. 231-237
[4.]
N.N. Zammitt, B.M. Frier.
Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities.
Diabetes Care, 28 (2005), pp. 2948-2961
[5.]
J. Rosenstock, G. Dailey, M. Maíz-Benedetti, A. Fristche, Z. Lin, A. Salzman.
Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Diabetes Care, 28 (2005), pp. 950-955
[6.]
J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, et al.
Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus.
Arch Intern Med, 165 (2005), pp. 1337-1344
[7.]
G.T. McMahon, R.A. Arky.
Inhaled insulina for diabetes mellitus.
N Engl J Med, 356 (2007), pp. 497-502
[8.]
R.A. DeFronzo, R.M. Bergenstal, W.T. Cefalu, J. Pullman, S. Lerman, B.W. Bode, Exubera Phase III Study Group, et al.
Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
Diabetes Care, 28 (2005), pp. 1922-1928
[9.]
J. Rosenstock, B. Zinman, L.J. Murphy, S.C. Clement, P. Moore, C.K. Bowering, et al.
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.
Ann Intern Med, 143 (2005), pp. 549-558
[10.]
P.A. Hollander, L. Blonde, R. Rowe, A.E. Mehta, J.L. Milburn, K.S. Hershon, et al.
Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
Diabetes Care, 27 (2004), pp. 2356-2362
[11.]
K. Hermansen, T. Ronnemaa, A.H. Petersen, S. Bellaire, U. Adamson.
Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.
Diabetes Care, 27 (2004), pp. 162-167
[12.]
H. Yki-Jarvinen, A. Dressler, M. Ziemen, HOE 901/3002 Study Group.
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes.
Diabetes Care, 23 (2000), pp. 1130-1136
[13.]
M.C. Riddle, J. Rosenstock, J. Gerich, The Insulin Glargine 4002 Study Investigators.
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Diabetes Care, 26 (2003), pp. 3080-3086
[14.]
A. Fritsche, M.A. Schweitzer, H.U. Haring, 4001 Study Group.
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Ann Intern Med, 138 (2003), pp. 952-959
[15.]
M. Massi-Benedetti, E. Humburg, A. Dressler, M. Ziemen.
A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
Horm Metab Res, 35 (2003), pp. 189-196
[16.]
M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, R. Gomis, For the AT.LANTUS Study Group.
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.
Diabetes Care, 28 (2005), pp. 1282-1288
[17.]
K. Hermansen, M. Davies, T. Derezinski, G. Martínez Ravn, P. Clauson, P. Home.
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Diabetes Care, 29 (2006), pp. 1269-1274
[18.]
T. Yoshihara, N. Kumashiro, Y. Kanazawa, T. Mita, Y. Sakurai, J. Kawai, et al.
Therapeutic efficacy of miglitinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Endocr J, 53 (2006), pp. 67-72
[19.]
J. Rosenstock, S.L. Schwartz, C.M. Clark, G.D. Park, D.W. Donley, M.B. Edwards.
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Diabetes Care, 24 (2001), pp. 631-636
[20.]
T. Haak, A. Tiengo, E. Draeger, M. Suntum, W. Waldhausl.
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Diabetes Obes Metab, 7 (2005), pp. 56-64
[21.]
K. Raslova, M. Bogoev, I. Raz, G. Leth, M.A. Gall, N. Hancu.
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
Diabetes Res Clin Pract, 66 (2004), pp. 193-201
[22.]
J.K. Malone, S. Bai, B.N. Campaigne, J. Reviriego, B. Augendre-Ferrante.
Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes.
Diabet Med, 22 (2005), pp. 374-381
[23.]
J.K. Malone, L.F. Kerr, B.N. Campaigne, R.A. Sachson, J.H. Holcombe, The Lispro Mixture-Glargine Study Group.
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Clin Ther, 26 (2004), pp. 2034-2044
[24.]
P. Raskin, E. Allen, P. Hollander, A. Lewin, R.A. Gabbay, P. Hu, The INITIATE Study Group, et al.
Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs.
Diabetes Care, 28 (2005), pp. 260-265
[25.]
H.U. Janka, G. Plewe, M.C. Riddle, C. Kliebe-Frisch, M.A. Schweitzer, H. Yki-Jarvinen.
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Diabetes Care, 28 (2005), pp. 254-259
[26.]
H.C. Gerstein, J.F. Yale, S.B. Harris, M. Issa, J.A. Stewart, E. Dempsey.
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
Diabet Med, 23 (2006), pp. 736-742
Copyright © 2008. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos